KGKrishnendu Ghosh

Krishnendu Ghosh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Krishnendu Ghosh has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Epigenetic alterations induced by ionizing radiation: pathways to cancer and prognostic strategies

    by Alisha Behera, Krishnendu Ghosh, Rambha Pandey, Archana Sharma, Gaura Kumar Rath, Amitava Adhikary, Ashok Sharma

    1. Ionizing radiation (IR) is a well-established carcinogenic agent capable of inducing both genetic and epigenetic alterations that contribute to malignant transformation (Becker et al. 2007; 2010...

  • Open Access

    Targeting the tumor microenvironment and mitochondrial dynamics: A theranostic frontier in cancer

    by Umesh Kumar, Lakshita Tyagi, Krishnendu Ghosh

    The tumor microenvironment (TME) is a dynamic and complex system comprising immune cells, stromal cells, blood vessels, and the extracellular matrix. The cellular and molecular elements can be different among cancer types, but they appear to be crucial for tumor initiation, survival, invasion, and metastasis. During early tumor development, cancer cells create a bidirectional relationship with TME components that allows them to evade immune detection, resist apoptotic processes, and promote angiogenesis and metastasis. Traditionally, cancer progression has been attributed simply to the sequential accumulation of genetic mutations. However, evidence is growing that epigenetic alterations, such as DNA methylation and hydroxymethylation, histone modifications, and microRNA dysregulation, are also important contributors to tumorigenesis. These epigenetic alterations also regulate critical signaling pathways related to apoptosis, autophagy, and cellular differentiation, which have implications for the emergence of aggressive cancer stem-like cells and further metastasis. The recognition of epigenetic regulatory mechanisms has also led to new therapeutic options. Epigenetic drugs, including DNA methyltransferase and histone deacetylase inhibitors, have been shown to reverse the expression of tumor suppressor genes, enhance the efficacy of conventional therapies, block the development of cancer progenitor cells, and reduce recurrence rates. Recognizing epigenetic dysregulation as a hallmark of cancer represents an opportunity to create new biomarkers and targeted treatments. Despite significant advances in surgery, chemotherapy, and radiotherapy, most standard treatments lack precision and typically have significant side effects. The movement toward immunotherapy, targeted therapy, and personalized medicine has allowed for more precise, less invasive, and more tolerable treatment regimens. At the same time, there has been an increasing recognition of the role of mitochondrial dynamics (such as fission, fusion, and mitophagy) as important regulators of tumor metabolism, drug resistance, and apoptosis. Although their clinical significance is still being fully explored, mitochondrial biomarkers and mitochondrial-targeted therapies present diagnostic and therapeutic value. Collectively, the degree to which the TME is responsive to different treatment modalities, the contribution of epigenetics, and the coordinated regulation of mitochondrial dynamics may contribute to a more informed theranostic application toward improving cancer diagnosis, treatment, and patient survival.


  • Open Access

    PI3K regulates TAZ/YAP and mTORC1 axes that can be synergistically targeted

    by Keith C. Garcia, Ali A. Khan, Krishnendu Ghosh, Souradip Sinha, Nicholas Scalora, Gillian DeWane, Colleen Fullenkamp, Nicole Merritt, Yuliia Drebot, Samuel Y. Yu, et al.

    Sarcomas are a heterogeneous group of cancers with few shared therapeutic targets. We show that PI3K signaling is frequently activated in sarcomas due to PTEN loss (in 30-60%), representing a common therapeutic target. The PI3K pathway has lacked a downstream oncogenic transcription factor. We show TAZ and YAP are transcriptional co-activators regulated by PI3K and drive a transcriptome necessary for tumor growth in a PI3K-driven sarcoma mouse model. This PI3K-TAZ/YAP axis exists in parallel to the known PI3K-Akt-mTORC1 axis providing a rationale for combination therapy targeting the TAZ/YAP-TEAD interaction and mTORC1. Combination therapy using IK-930 (TEAD inhibitor) and everolimus (mTORC1 inhibitor) synergistically diminished proliferation and anchorage dependent growth of PI3K-activated sarcoma cell lines at low, physiologically achievable doses. Furthermore, this combination therapy showed a synergistic effect in vivo, suggesting that an integrated view of PI3K and Hippo signaling can be leveraged therapeutically in PI3K activated sarcomas.


  • Open Access

    Genomic, Epigenomic, and Immuno-Genomic Regulations of Vitamin D Supplementation in Multiple Sclerosis: A Literature Review and In Silico Meta-Analysis

    by Preetam Modak, Pritha Bhattacharjee, Krishnendu Ghosh

    Multiple sclerosis (MS) is a chronic autoimmune neurodegenerative disorder characterized by progressive demyelination and axonal degeneration within the central nervous system, driven by complex genomic and epigenomic dysregulation. Its pathogenesis involves aberrant DNA methylation patterns at CpG islands of numbers of genes like OLIG1 and OLIG2 disrupting protein expression at myelin with compromised oligodendrocyte differentiation. Furthermore, histone modifications, particularly H3K4me3 and H3K27ac, alter the promoter regions of genes responsible for myelination, affecting myelin synthesis. MS exhibits chromosomal instability and copy number variations in immune-regulatory gene loci, contributing to the elevated expression of genes for pro-inflammatory cytokines (TNF-α, IL-6) and reductions in anti-inflammatory molecules (IL-10, TGF-β1). Vitamin D deficiency correlates with compromised immune regulation through hypermethylation and reduced chromatin accessibility of vitamin D receptor (VDR) dysfunction and is reported to be associated with dopaminergic neuronal loss. Vitamin D supplementation demonstrates therapeutic potential through binding with VDR, which facilitates nuclear translocation and subsequent transcriptional activation of target genes via vitamin D response elements (VDREs), resulting in suppression of NF-κB signalling, enhancement of regulatory T-cell (Treg) responses due to upregulation of specific genes like FOXP3, downregulation of pro-inflammatory pathways, and potential restoration of the chromatin accessibility of oligodendrocyte-specific gene promoters, which normalizes oligodendrocyte activity. Identification of differentially methylated regions (DMRs) and differentially expressed genes (DEGs) that are in proximity to VDR-mediated gene regulation supports vitamin D supplementation as a promising, economically viable, and sustainable therapeutic strategy for MS. This systematic review integrates clinical evidence and eventual bioinformatical meta-analyses that reference transcriptome and methylome profiling and identify prospective molecular targets that represent potential genetic and epigenetic biomarkers for personalized therapeutic intervention.


  • Open Access

    Cellular and molecular characteristics of low-grade central nervous system tumors revealing modulations in Ki-67/propidium iodide, MMP2, VEGFR2, and CD11b/Iba1: Analyses of post-operative samples

    by Krishnendu Ghosh, Pritha Bhattacharjee, Anirban Ghosh

    The World Health Organization’s 2016 and 2021 classifications of central nervous system (CNS) tumors emphasize the integration of histopathological and molecular profiling for improved prognostic and therapeutic precision. Understanding the molecular hallmarks of low-grade CNS tumors is essential for enabling precision therapies and minimizing off-target effects while preventing malignant transformation. This study investigated key oncogenic features in surgically resected low-grade CNS tumors of varying cellular lineages and anatomical locations, alongside associated clinical metadata. Tumors were histologically classified and analyzed for molecular markers using immunohistochemistry, immunofluorescence microscopy, and flow cytometry. Assessed hallmarks included proliferation (Ki-67, propidium iodide index), invasiveness (matrix metalloproteinase [MMP]-2), neovascularization (vascular endothelial growth factor receptor 2 [VEGFR2], epigenetic modulation (DNA methyltransferase 1 [DNMT1], and immune microenvironment (Cluster of Differentiation 11b [CD11b], Iba1, silver-gold macrophage staining). Statistical analyses included t-tests, one-way ANOVA, and Kruskal–Wallis tests (p<0.05). In diffuse astrocytoma and myxopapillary ependymoma, a proliferation–invasion dichotomy was observed, with lower-proliferative ependymomas exhibiting higher MMP-2 expression. Astrocytomas exhibited elevated DNMT1 expression, indicative of increased epigenetic alterations. Immune profiling revealed tumor-specific differences: CD11b+ macrophages were more prominent in meningiomas, while Iba1+ microglia were enriched in astrocytomas, reflecting distinct immune microenvironments. Despite their low-grade classification, these tumors demonstrated hallmark cancer characteristics, variably expressed across astrocytoma, ependymoma, and meningioma. The combined assessment of Ki-67, MMP-2, VEGFR2, DNMT1, CD11b, and Iba1 provides a prognostically informative and therapeutically exploitable profile. These findings support the integration of molecular profiling into risk stratification and adjunctive treatment strategies to improve prognosis and reduce malignant progression in low-grade CNS tumors.

  • Open Access

    Cellular and Molecular Characteristics of Low-Grade CNS Tumours Depicting Ki67/PI, MMP2, VEGFR, CD11b/Iba1 Modulations: Studies on Post-Operative Samples

    by Krishnendu Ghosh, Pritha Bhattacharjee, Anirban Ghosh

    Background: The brain tumour classification of WHO in 2016 introduced molecular characterization of samples with histopathology, and that was further elaborated in 2021. Detecting the characteristic state of the tumour to promote prognostic outcome is now a key interest area of present cancer research. This work aims to explore such important aspects from the low-grade post-operative CNS tumour samples. Methods: Post-ablative samples of low-grade CNS tumours were collected from hospital with patient metadata, identified and graded histopathologically. They were characterized with selective protein expressions indicating hallmark characters of cancer like proliferation denoted by Ki67 and PI index, metastatic potency by MMP2, neovasculogenic ability by VEGFR2 and epigenetic alterations by DNMT1 and macrophage infestation by silver-gold staining, CD11b and Iba1 using immunohistochemistry (IHC), immunofluorescence (IF) microscopy and flowcytometry. Results: In low-grade diffuse astrocytoma and myxopapillary ependymoma, survival and recurrence are finely tuned with an inverse relationship of proliferation and invasion with neovascularization eliciting a multivariate prognostic cue. Matrix degrading tendency found higher in less-proliferative ependymoma, indicating proliferation-invasion dichotomy. Global epigenetic changes denoted by DNMT1 found prominent in low-grade astrocytoma, higher infiltrated CD11b+ macrophages appeared in meningioma, whereas low-grade astrocytoma showed increased Iba1+ microglia. Conclusion: The study showed that even low-grade CNS tumours can elicit hallmark characteristics of cancer and distinctive features among astrocytoma, ependymoma and meningioma along with information on tumour associated macrophages using a cocktail of common markers Ki67 and PI indexing, MMP2, VEGFR2 CD11b/Iba1 and DNMT1 expressions with profound prognostic importance.

  • Novel Variants of IGF2 Gene Are Linked With Neural Tube Defects‐An In Silico to Clinical Approach in West Bengal, India

    by Nirvika Paul, Susanta Sadhukhan, Srilagna Chatterjee, Anwesha Das, Dinesh Munian, Kausik Ganguly, Biswabandhu Bankura, Krishnendu Ghosh, Sudakshina Ghosh, Madhusudan Das

    Background: Neural tube defects (NTDs) are defined as an incomplete closure of the neural tube (NT), with a prevalence of 1.2 per 1000 live births around the world. Methylation of the maternally imprinted gene Insulin‐like growth factor 2 (IGF2) is one of the epigenetic mechanisms that contribute significantly to the development of NTDs. Its important functions are the fetal growth and metabolism, as well as cell division and differentiation.Objectives: In a couple of studies, individual changes in IGF2 with single nucleotide variants (SNVs) have been found to be linked with NTDs as well as with other diseases. However, there is more need of studying so that we can better understand precisely this mechanism at the molecular level. In this study we tried to investigate the relationship between genetic variants of IGF2 and NT closure by screening all SNVs of IGF2 using both in silico methods and clinical experiments on human samples.Methods: We enrolled 98 consecutive mothers carrying fetuses with NTDs as cases and 76 age‐matched mothers with healthy babies as controls. Following an in silico analysis of the IGF2 gene, we designed three primers targeting a total of 180 exonic, 579 intronic, and 46 variants in the 3′ untranslated region (3′ UTR) for polymerase chain reaction (PCR) and subsequent sequencing. Statistical analyses were performed to assess associations between these genetic variants and NTDs. Additionally, quantitative real‐time PCR (qRT‐PCR) was conducted to analyze the mRNA expression levels of the target gene.Results: This is the first study to enlist 11 non‐synonymous variants [rs750845881(D93N), rs1290256492(P87H), rs755066389(P87T), rs150610908(G65D), rs762200142(R64C), rs868067982(G49C), rs778465733(R48L), rs1018841144(R48C), rs1057518115(C33R), rs112276039(C22R), rs1240151267(L16W)] in the regulation of IGF2 gene functions through in silico analysis. Further clinical validation in maternal samples showed a significant association between rs3213225 (C > T) (OR‐2.076; CI‐1.123‐3.840; p‐0.0209) and rs734351 (C > T) (OR‐2.148; CI‐1.167‐3.956; p‐0.0148) with increased disease risk. RNA expression study validated and supported all of these SNVs, indicating a strong correlation with NTD.Conclusions: Our research strongly suggests that genetic variations in IGF2 may help explain the risk association with NTDs and could be valuable for diagnostic and therapeutic applications.